In findings published in Clinical Cancer Research, a research team at Mayo Clinic identified specific proteins—fibronectin and smooth muscle actin—within colorectal cancer tissues that are associated with resistance to immunotherapy treatment.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe